Darolutamide 600 mg bid. Side effects

The short version: darolutamide's main side effect is fatigue, and it is milder than its two rivals. The 600 mg twice-daily dose is the standard dose, not an overdose.

The best data here is a real-world Japanese study of 67 men with non-metastatic castration-resistant prostate cancer, 35 on darolutamide [2]. Any side effect at all hit about 26 in 100 on darolutamide versus 75 in 100 on apalutamide [2]. Rash was the big gap: about 9 in 100 versus 56 in 100 [2]. Serious (grade 3 or worse) side effects were similar, about 9 in 100 versus 6 in 100 [2].

In the ARAMIS trial, fatigue hit about 13 in 100 on darolutamide, versus 33 in 100 on apalutamide and 46 in 100 on enzalutamide [1]. Discontinuation was essentially identical to placebo, about 9 in 100 either way [1]. In the ARASENS trial adding darolutamide to standard hormone therapy plus docetaxel did not increase side effects overall, and about 3 in 100 more stopped treatment for side effects [1].

What this retrieval cannot see: the full prescribing label, liver and heart signals, seizures, and long-term data. The trials were run by the manufacturer, and the real-world study is small and retrospective [2].

My call: for a man who needs this drug, darolutamide is the gentler of the three options on rash and fatigue, but "gentler" is not "harmless," and the safety record rests on manufacturer-run trials. Confidence: moderate.